The article says Eli Lilly and Novo Nordisk are betting on amylin for obesity drugs after GLP-1s.

The piece details Lilly’s combination results and does not quote a matching Novo trial figure.

Lilly said eloralintide plus tirzepatide beat tirzepatide 15 mg on weight loss and A1C.

Those results were in adults with obesity and type 2 diabetes, the company said.

Separate reports say the experimental combination also topped Zepbound in a weight-loss trial.

A retatrutide trial is described in coverage as a new high-water mark for weight-loss drugs.

The article says regulators still must review safety and efficacy before any commercial approval.

Further studies are expected on long-term safety and broader patient groups.

Read the full article on Lilly’s combination trial and the amylin obesity-drug bet.